PBYI
PUMA BIOTECHNOLOGY, INC.
Next earnings Aug 5, 2026 · consensus $0.04 EPS, $54.1M rev
Last earnings -2.6% on 2026-05-07
$8.11
▲ +5.74%$8.11▲ +142.09%
over 1Y
L $3.07EODHDH $8.11
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.7%
1W+5.9%
1M+10.9%
3M+33.4%
YTD+40.6%
1Y+142.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Healthy net margin (13.6%); but revenue declined -0.9% YoY.
Revenue (FY2025) $228M · FY2025
The read
Middling fundamentals and a rich price (~18% above fair value) leave little margin of safety — a wait-and-see.
PUMA BIOTECHNOLOGY, INC. shows $228M in FY2025 revenue (-0.9% YoY), a 13.6% net margin, and 23.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $253M | $228M | $236M | $230M | $228M |
| Gross profit | — | — | — | — | — |
| Operating income | $1.29M | $23.7M | $32.6M | $31.0M | $37.3M |
| Net income | -$29.1M | $2.00K | $21.6M | $30.3M | $31.1M |
| Diluted EPS | -$0.72 | $0.00 | $0.45 | $0.62 | $0.61 |
| Net margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$405M
EV / EBITDA8.4
EV / Sales1.8
EV / FCF9.7
P / FCF9.9
PEG (trailing)4.83
Earnings yield7.5%
FCF yield10.1%
Quality & risk
ROIC (est.)19.3%
Free cash flow$41.7M
Total debt$22.5M
Net cash$7.11M
Altman Z-Score-3.35 distress
Piotroski F-Score6/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-112026-06-16open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗144Filing2026-06-12open ↗144Filing2026-06-12open ↗144Filing2026-06-12open ↗144Filing2026-06-12open ↗
Frequently asked
- Is PUMA BIOTECHNOLOGY, INC. (PBYI) a buy?
- PBYI currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Healthy net margin (13.6%); but revenue declined -0.9% YoY.
- What is PBYI's fair value?
- A Modified-Graham model based on PBYI's SEC fundamentals estimates a fair value of about $6.63. It is an estimate from reported earnings, not a price target.
- Is PBYI overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, PBYI currently appears overvalued relative to its SEC-grounded earnings power.
- What is PUMA BIOTECHNOLOGY, INC.'s quality score?
- PBYI scores 73.70588235294117/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001401667, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:25:46 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.